

3rd MELANOMA WORKSHOP

JUNE 30 / JULY 2, 2011
IFOM-IEO CAMPUS
MILAN, ITALY

3rd Melanoma Workshop 2011

IFOM-IEO Campus, Milan, Italy

[Thursday, June 30, 2011](#)

[Friday, July 1, 2011](#)

[Saturday, July 2, 2011](#)

SCIENTIFIC PROGRAM

Thursday, June 30, 2011

h. 13.00-14.00 Registration to the meeting

h. 14.00-14.30 Welcome and introduction (L. Lanfrancone)

h. 14.30-16.30 Transcriptional regulation in melanoma, I Chairperson: L. Larue

h. 14.30/15.00 **Colin Goding**, Oxford, UK
Signalling phenotype switching in melanoma subpopulations

h. 15.00/15.30 **Keith Hoek**, Zurich, Switzerland
Signalling and epigenetics of melanoma cell phenotype switching

h. 15.30/16.00 **Eirikur Steingrimsón**, Reykjavik, Iceland
Mitf: structure and a novel target gene

h. 16.00/16.15 **Phil Cheng**, Zurich, Switzerland
DNA methylation in melanoma phenotype switching

h. 16.15/16.30 b, Zurich, Switzerland
The role of hypoxia in melanoma phenotype switching

h. 16.30/17.00 Coffee break

h. 17.00-18.30 Transcriptional regulation in melanoma II Chairperson: C. Goding

h. 17.00/17.30 **Robert Ballotti**, Nice, France
Identification of the molecular mechanisms controlling the switch between melanoma initiating cells and their differentiated progeny

h. 17.30/18.00 **Irwin Davidson**, Illkirch, France
Defining the MITF interactome

h. 18.00/18.15 **Nicola Schoenewolf**, Zurich, Switzerland
What's the role of KIT in acrolentiginous and mucosal melanoma cell cultures?

h. 18.15/18.30 **Gianluca Civenni**, Zurich, Switzerland
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth

Friday, July 1, 2011

h. 9.30-11.30 Senescence in melanoma Chairperson: F. d'Adda di Fagagna

h. 9.30/10.00 **Dan Peeper**, Amsterdam, The Netherlands
Senescence and melanoma progression

h. 10.00/10.30 **Dot Bennett**, London, England
Melanoma: why is the radial growth phase radial?

h. 10.30/11.00 **Svenja Meierjohann**, Würzburg, Germany
Senescence evasion in melanoma

h. 11.00/11.15 **Giovanna Chiorino**, Biella, Italy
BRAFV600E nevi are protected from malignant transformation through modulation of apoptosis, autophagy, and senescence genes

h. 11.15/11.30 **Fabrizio d'Adda di Fagagna**, Milan, Italy
Molecular mechanisms of cellular senescence

h. 11.30-12.00 COFFEE BREAK

h. 12.00-13.30 Animal models in melanoma Chairperson: M. Mione

h. 12.00/12.30 **Marina Mione**, Milan, Italy
Genetic and epigenetic modifiers of cancer progression: insights from zebrafish melanoma models

h. 12.30/13.00 **Carola Ponzetto**, Turin, Italy
An animal model of Met-mediated melanoma as a tool to test Met inhibitors

h. 13.00/13.15 **Grant Wheeler**, Norwich, United Kingdom
Small molecule screens in Xenopus identify inhibitors of pigment cell development, neural crest development and melanoma growth

h. 13.15/13.30 **Olga Shakhova**, Zurich, Switzerland
Melanocyte stem cells are the cells of origin of melanoma and require Sox10 for tumorigenesis

h. 13.30-15.00 LUNCH

h. 15.00-16.30 Molecular pathways and targeted therapies I Chairperson: PF. Ferrucci

h. 15.00/15.30 **Lionel Larue**, Paris, France
Pou3f2 affects both migration and proliferation in vitro and in vivo

h. 15.30/16.00 **Marisol Soengas**, Madrid, Spain
TBA

h. 16.00/16.15 **Elisa Penna**, Turin, Italy
microRNA-214 contributes to melanoma tumor progression through suppression of TFAP2C

h. 16.15/16.30 **Chiara Martinoli**, Milan, Italy
Evaluation of maspin expression in primary tumors of melanoma patients: evidences for prognostic significance

h. 16.30-17.00 COFFEE BREAK

h. 17.00-18.00 Molecular pathways and targeted therapies, II Chairperson: L. Lanfrancone

h. 17.00/17.30 **Ze'ev Ronai**, La Jolla, USA
PKC epsilon control of ATF2 limits its mitochondrial function in melanoma

h. 17.30/17.45 **Benedetta Belloni**, Zurich, Switzerland
Phenotype-specific response of melanoma cells to HDAC inhibition

h. 17.45/18.00 **Ranjan Perera**, Orlando, United States
The regulation of noncoding RNAs (miRNAs and large noncoding RNAs) and their role in melanoma development in humans

Saturday, July 2, 2011

h. 9.00-10.15 Novel advances in immunotherapy I Chairperson: M. Rescigno

h. 9.00/9.30 **Gosse Adema**, Nijmegen, The Netherlands
Dendritic cells in immunotherapy of cancer

h. 9.30/10.00 **Pedro Romero**, Lausanne, Switzerland
Harnessing adaptive and innate immunity for the therapy of melanoma

h. 10.00/10.15 **Fabiana Saccheri**, Milan, Italy
Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity

h. 10.15-10.45 COFFEE BREAK

h. 10.45-12.15 Novel advances in immunotherapy II Chairperson: P. Romero

h. 10.45/11.15 **Licia Rivoltini**, Milan, Italy
Myeloid-derived suppressor cells in melanoma patients: genesis and role in tumor-mediated immune suppression

h. 11.15/11.45 **Donata Rimoldi**, Lausanne, Switzerland
Comprehensive genomic profiling of seven cutaneous melanomas

h. 11.45-12.15 **Pier Francesco Ferrucci**, Milan, Italy
Targeted therapies as new strategies for the treatment of metastatic melanoma

h. 12.15-12.30 Open discussion and closing remarks (M. Rescigno)

h. 12.30-13.30 LUNCH

End of the workshop